Brief: Compass Therapeutics Announces Phase 2 Data Of CTX-009 Will Be Presented At ASCO GI Cancers Symposium
19/01/2023 22:03
Jan 19 (Reuters) - Compass Therapeutics Inc. CMPX.O :
* COMPASS THERAPEUTICS ANNOUNCES THAT THE PHASE 2 DATA OF
CTX-009
IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH BILIARY TRACT
CANCERS (BTC) WILL BE PRESENTED AT THE ASCO GI CANCERS SYMPOSIUM
ON JANUARY 20, 2023
Source text for Eikon: ID:nGNXbQ8btP
Further company coverage: CMPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback